Podcast 294: PD-1 blockade in locally advanced rectal cancer

Locally advanced rectal cancer usually receives a three-part treatment: chemotherapy followed by radiotherapy and then surgery. In a small-cohort study presented at this year’s ASCO conference researchers used a PD-1 inhibitor — dostarlimab — every three weeks for 6 months against the disease. All patients had mismatch repair deficient tumors. No other treatments were needed however, since the 12 patients all attained complete response if they completed the regimen. As part of the NEJM Group’s coverage of ASCO, Christine Sadlowski interviewed the study’s first author, Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Centern about the study and its implications. The study as published in the New England Journal of Medicine The post Podcast 294: PD-1 blockade in locally advanced rectal cancer first appeared on Clinical Conversations .

You can listen to Podcast 294: PD-1 blockade in locally advanced rectal cancer online on Radio and Podcast. Open the player on this page to stream the available audio.

Podcast 294: PD-1 blockade in locally advanced rectal cancer is an episode from Clinical Conversations » Podcast Feed by NEJM Group.

This episode is 13:08 long.

This episode was published on Jun 29, 2022.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Clinical Conversations » Podcast Feed when more episodes are available from the podcast feed.